US 11235059
Afucosylated anti-FGFR2IIIB antibodies
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 11235059 (Afucosylated anti-FGFR2IIIB antibodies) held by Five Prime Therapeutics, Inc. expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Five Prime Therapeutics, Inc.
- Grant date
- Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 59
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K2039/54, A61K2039/545